tbuckley/cabot-search huggingface dataset:
STRATEGIES OF LEFT VENTRICULAR UNLOADING DURING VA-ECMO SUPPORT
Authors: Luca Baldetti, Mario Gramegna, Alessandro Beneduce, Francesco Melillo, Francesco Moroni, Francesco Calvo, Giulio Melisurgo, Silvia Ajello, Evgeny Fominskiy, Federico Pappalardo, Anna Mara Scandroglio
Journal: Journal of the American College of Cardiology (2020)
STUDY DESIGN AND RATIONALE OF HELIOS-B: A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
Authors: Rebecca Shilling, Verena Karsten, Nancy Silliman, Jihong Chen, Wei Li, John Vest
Journal: Journal of the American College of Cardiology (2020)
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
Authors: Rita Rubin
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IMPACT OF POLYVASCULAR DISEASE ON SEVERITY OF CORONARY ARTERY DISEASE AND CLINICAL OUTCOME IN PATIENTS WITH STABLE ANGINA
Authors: Koji Yanaka, Hirokuni Akahori, Takahiro Imanaka, Kojiro Miki, Nagataka Yoshihara, Toshio Kimura, Takamasa Tanaka, Masanori Asakura, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2020)
A GHOST LEFT BEHIND AFTER TRANSVENOUS LEAD EXTRACTION: A FINDING TO BE FEARED
Authors: Rayan El-Zein, Mitchell Stelzer, John Hatanelas, Goodlive Thomas, Sreedhar Billakanty, Nagesh Chopra, Eugene Fu, Steven D. Nelson, Allan J. Nichols, Gregory Kidwell, James Kleman, Dennis A. Calnon, Karanvir S. Grewal, Todd G. Matros, Jayanta T. Mukherjee, David R. Richards, Akira Wada, Anish Amin
Journal: Journal of the American College of Cardiology (2020)
Provider-patient communication about cost of care: Results from a national patient education program.
Authors: Ivy A. Ahmed, Allison Harvey, Marni Amsellem, Thomas J. Smith
Journal: Journal of Clinical Oncology (2013)

9578 Background: A 2010 NIH study indicates direct cancer care expenditures will reach $158 billion in the U.S. by 2020, impacting millions of Americans. The cost of insurance for a family of 4 has increased from $6000 (2000) to over $16,000 (2011). Medical debt is a significant cause of personal bankruptcy, even if insured. The financial realities posed by costs associated with cancer care greatly complicate a cancer diagnosis. The most recent American College of Physicians Ethics Manual recommends all parties must interact honestly, openly, and fairly. (Snyder L, et al. Ann Int Med 2012, p86) This analysis explores the occurrence and value of patient-provider communication surrounding costs associated with care in a national survey of those affected by cancer. Methods: From 2011-12, 505 individuals attending Frankly Speaking About Cancer: Coping with the Cost of Care workshops completed a survey assessing experiences about the costs of cancer care. This is a Cancer Support Community national evidence-based educational program. All attendees (n=708) were eligible to complete survey. Results: Most attendees (71.3%) responded. The majority (62.4%) were people with cancer/survivors; the remainder included spouses/partners, family members, and 8.7% were health care professionals. Most (80.8%) were Caucasian, and averaged 57.2 years. Of those with cancer, 89.9% were insured at diagnosis. 59.4% reported no one on their health care team initiated a discussion about the financial aspects of their care. Included in this figure, 22.7% actively sought information from health care team, and 36.7% received no information about cost. When topic was initiated, it was by social workers (16.2%), physicians (12.3%), nurses (6.3%) or financial specialists (8.2%). When information was provided, 72.1% found it somewhat or very useful. Also, regardless of provider discussion, respondents independently sought resources for managing costs, such as other patients (44.2%), the Internet (41.5%), and patient support organizations (38.1%). Conclusions: Patients want financial information but do not receive it. These data highlight the need and value of providers initiating a dialogue about the cost of cancer care with patients.
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan
Authors: Senthil Selvaraj, Brian L. Claggett, Michael Böhm, Stefan D. Anker, Muthiah Vaduganathan, Faiez Zannad, Burkert Pieske, Carolyn S.P. Lam, Inder S. Anand, Victor C. Shi, Martin P. Lefkowitz, John J.V. McMurray, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2020)
PULSED ULTRASOUND COMBINED WITH ACOUSTIC PHASE-CHANGE NANOPARTICLES DISSOLVE PORCINE CORONARY ARTERY THROMBUS IN VIVO
Authors: Nan Jiang, Bo Hu, Sheng Cao, Qing Zhou, Qing Deng, Jinling Chen, Rui-Qiang Guo
Journal: Journal of the American College of Cardiology (2020)
A SMALL DISSECTION LEAD TO A BIG DIAGNOSIS
Authors: Tikal Kansara, Monil Majmundar, Joanna Lenik, Abdullah Zoheb Azhar, Adedoyin Akinlonu, Gerald Pekler, Ferdinand Visco, Annapoorna Subhash Kini, Savi Mushiyev
Journal: Journal of the American College of Cardiology (2020)
Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users
Authors: Morten Hasselstrøm Jensen, Mads Kjolby, Ole Hejlesen, Poul Erik Jakobsen, Peter Vestergaard
Journal: Diabetes Care (2020)

OBJECTIVE The vast number of antihyperglycemic medications and growing amount of evidence make clinical decision making difficult. The aim of this study was to investigate the safety of antihyperglycemic dual and triple therapies for type 2 diabetes management with respect to major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality in a real-life clinical setting. RESEARCH DESIGN AND METHODS Cox regression models were constructed to analyze 20 years of data from the Danish National Patient Registry with respect to effect of the antihyperglycemic therapies on the three end points. RESULTS A total of 66,807 people with type 2 diabetes were treated with metformin (MET) plus a combination of second- and third-line therapies. People on MET plus sulfonylurea (SU) had the highest risk of all end points, except for severe hypoglycemia, for which people on MET plus basal insulin (BASAL) had a higher risk. The lowest risk of major adverse cardiovascular events was seen for people on a regimen including a glucagon-like peptide 1 (GLP-1) receptor agonist. People treated with MET, GLP-1, and BASAL had a lower risk of all three end points than people treated with MET and BASAL, especially for severe hypoglycemia. The lowest risk of all three end points was, in general, seen for people treated with MET, sodium–glucose cotransporter 2 inhibitor, and GLP-1. CONCLUSIONS Findings from this study do not support SU as the second-line treatment choice for patients with type 2 diabetes. Moreover, the results indicate that adding a GLP-1 in people treated with MET and BASAL could be considered, especially if those people suffer from severe hypoglycemia.
USE OF MACHINE LEARNING METHODOLOGY TO FIND PREDICTORS OF ALL-CAUSE MORTALITY IN THE TREATMENT OF PRESERVED CARDIAC FUNCTION HEART FAILURE WITH AN ALDOSTERONE ANTAGONIST TRIAL (TOPCAT)
Authors: Gauri Dandi, Nuha Gani, Zyannah Mallick, Victoria Xin, Ian Atkinson, Avantika Banerjee, Anwar Husain, Adrita Ashraf, Xin Tian, Colin Wu, Tejas Patel, Anna Kettermann, Rodica Ciurea, Natalie Lewis, Danielle Jateng, George Sopko, Carlos Cure, Gyorgy Csako, Keith Burkhart, Victor Crentsil, Amit Dey, Eileen Navarro, Frank Pucino, Yves Rosenberg, Ahmed Hasan
Journal: Journal of the American College of Cardiology (2020)
In AF, DOACs were linked to lower risk for osteoporotic fractures at 2 years compared with VKAs
Authors: Andrew Dunn
Journal: Annals of Internal Medicine (2020)

Source Citation Binding C, Bjerring Olesen J, Abrahamsen B, et al. Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants. J Am Coll Cardiol. 2019;74:2150-8. 31648707
Matt Morgan: When the problem is urgent and important
Authors: Matt Morgan
Journal: BMJ (2020)

Eisenhower said that “what is important is seldom urgent and what is urgent is seldom important.” Breaching a waiting list target—urgent! Celebrity admission to hospital—urgent! But major future events that will almost certainly cause death and disruption, from the climate emergency to pandemic disease? Not urgent. Yet now we have a crisis that’s both urgent and important.

The health systems of many countries are about to face unprecedented demand, in systems that are already under pressure—like a cardiac arrest in a body that already carries the scars of chronic, untreated disease. We may soon face a situation where demand for intensive care exceeds …
LEAN NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH INCREASED PREVALENCE AND INCIDENCE OF CARDIOMETABOLIC DISORDERS
Authors: Ehimen Aneni, Marcio Bittencourt, Michael Blaha, Ahmed Soliman, Mouaz H. Al-Mallah, Matthew J. Budoff, Raul D. Santos, Khurram Nasir
Journal: Journal of the American College of Cardiology (2020)
THE COMBINATION OF HEMATOPOIETIC AND ENDOTHELIAL PROGENITOR CELLS IMPROVES PREDICTION OF OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Devinder Dhindsa, Pratik Sandesara, Qingchun Jin, Chang Liu, Anurag Mehta, Ayman Alkhoder, Ayman Samman Tahhan, Ali Mokhtari, Iraj Hesaroieh, Edmund Waller, Laurence S. Sperling, Arshed A. Quyyumi
Journal: Journal of the American College of Cardiology (2020)
USEFULNESS OF LEFT ATRIAL SPECKLE TRACKING ECHOCARDIOGRAPHY IN PREDICTING RECURRENCE OF ATRIAL FIBRILLATION AFTER RADIOFREQUENCY ABLATION: A META-ANALYSIS
Authors: Anne Bjerg Nielsen, Kristoffer Skaarup, Mats Højbjerg Lassen, Kasper Djernaes, Morten Hansen, Jesper Hastrup Svendsen, Arne Johannessen, Jim Hansen, Samuel Soerensen, Gunnar Gislason, Tor Biering-Sorensen
Journal: Journal of the American College of Cardiology (2020)
PROSTHESIS-PATIENTS MISMATCH DEFINED BY COMPUTED TOMOGRAPHY AND MORTALITY AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Miho Fukui, Liang Tang, John R. Lesser, Go Hashimoto, Hiroki Niikura, Santiago Garcia, Mario Gossl, Paul Sorajja, Joao L. Cavalcante
Journal: Journal of the American College of Cardiology (2020)
HSR20-086: Concurrent Chemoradiation Treatment Patterns for Stage III Non-Small Cell Lung Cancer in Veterans
Authors: Anna Hung, Kyung Min Lee, Yanhong Li, Julie A. Lynch, Pradeep Poonnen, Bradley J. Hintze, Olga V. Efimova, Candice Yong, Brian Seal, Trudy Pendergraft, Michael Kelley, Shelby D. Reed
Journal: Journal of the National Comprehensive Cancer Network (2020)
c-Maf: a bad influence in the education of macrophages
Authors: Jose R. Conejo-Garcia, Paulo C. Rodriguez
Journal: Journal of Clinical Investigation (2020)

Tumor-associated macrophages (TAMs) represent the most abundant hematopoietic cell type in the solid tumor microenvironment. TAMs drive T cell inhibition, promote angiogenesis, and produce tumor growth factors. Although they can paradoxically exert antitumor activity and prime protective immunity, the pathways driving this phenotype remain unclear. In this issue of the JCI, Liu and colleagues identified the c-Maf transcription factor as a master regulator of protumoral TAM polarization. The authors found that c-Maf promoted TAMs' immunosuppressive activity, governed their metabolic programming, and drove expression of the macrophage differentiation protein, CSF1R. Further, inhibiting c-Maf in myeloid progenitors, and consequent myeloid-lineage cells, including TAMs, delayed tumor growth. Importantly, β-glucan treatment reduced c-MAF expression in macrophages and monocytes from patients with non-small cell lung cancer (NSCLC) where c-MAF is overexpressed. These results reveal mechanisms whereby myeloid cells drive human cancer progression by thwarting protective immunity and could lead to immunotherapy for most solid malignancies.
Dynamic treatment regimen analysis to determine which treatment sequence can prolong survival of NSCLC patients.
Authors: Taro Koba, Fumio Imamura, Satoshi Morita, Masahide Mori, Kiyoshi Komuta, Takashi Kijima, Yoshinobu Namba, Kazumi Nishino, Suguru Yamamoto, Ryo Takahashi, Yukie Nakazawa, Seigo Minami, Yoshitaka Ogata, Atsushi Kumanogoh
Journal: Journal of Clinical Oncology (2013)

e19010^ Background: We often experience the re-challenge of EGFR-TKI on practice. However, it has not been reported which treatment sequence for EGFR-TKI re-challenge will contributes to long-term survival of NSCLC patients. Methods: We extracted information from retrospective cohort of advanced NSCLC patients with the following inclusion criteria: 1) Japanese patients who were diagnosed by October 2010 and treated with gefitinib after July 2002. 2) Performance status (PS) 0-2. 3) PR, CR, or long SD (6 months or more) by gefitinib. 4) Patients who had not received curative surgical operation or radiation therapy. The primary objective was to evaluate the effects of treatment histories on Overall Survival (OS). We also conducted a “Dynamic Treatment Regimen Analysis (DTRA)”. DTRA can be used to compare multiple treatment strategies/sequences in terms of time-to-event data like overall survival time. Results: A total of 335 NSCLC patient details were extracted. Sixty five patients experienced gefitinib re-challenge. There was a statistical difference in OS between gefitinib re-challenge group and non re-challenge group (median OS was 1272 days vs 774 days; p&lt;0.001). We confirmed this result using DTRA, “Gefitnib-Singlet chemo-Gefitinib” treatment sequence extended survival most out of all treatment sequence. Conclusions: This study suggests that gefitinib re-challenge may have significant affects on OS in long survivors after responding gefitinib treatment. Clinical trial information: UMIN000006913. [Table: see text]
Effect of dasatinib, a SRC kinase inhibitor, on lung cancer cells with defined epidermal growth factor receptor status
Authors: E. B. Haura, L. Song, F. Lee, R. Jove
Journal: Journal of Clinical Oncology (2006)

3019 Background: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict sensitivity to small molecule inhibitors of EGFR such as gefitinib and erlotinib. Importantly, mutant EGFR selectively activates Akt and STAT pathways that are important in NSCLC cell survival. SRC-family kinases can cooperate with receptor tyrosine kinases to signal through downstream molecules such as PI3K/PTEN/Akt and STATs. Despite the importance of EGFR signaling in lung cancer, the known cooperation between EGFR and SRC proteins, and evidence of elevated SRC activity in human lung cancers, the effect of SRC inhibition on cell fate is unknown. Methods: We evaluated the anti-tumor efficacy of a novel orally bioavailable SRC-ABL inhibitor dasatinib (BMS-354825) in non-small cell lung cancer cell lines with defined EGFR status including wildtype EGFR and mutant EGFR sensitive to gefitinib. Western blotting was used to evaluate the effect of dasatinib on downstream signaling pathways and in vitro assays were used to evaluate the effect cell cycle, apoptosis, and cell invasion. Results: Our results show that cell fate (death versus growth arrest) in lung cancer cells exposed to a SRC inhibitor is dependent on EGFR status. Dasatinib reduces mutant EGFR lung cancer cell viability through the induction of apoptosis and G1 cell cycle arrest while having no significant apoptotic effect on cell lines with wildtype EGFR. The induction of apoptosis in EGFR mutant cell lines corresponds to downregulation of phosphorylated Akt and Stat3 survival proteins. In cell lines without EGFR mutation, dasatinib induces a G1 cell cycle arrest with associated changes in cyclin D and p27 proteins as well as inhibits activated FAK and prevents tumor cell invasion. Conclusions: Our results demonstrate that novel SRC inhibitors could be effective therapy for patients with lung cancers through disruption of cell growth, survival and tumor invasion. Our results suggest EGFR status is critical in deciding cell fate in response to SRC inhibition. [Table: see text]
Chemokine receptors as novel targets of the oncogene Notch1 in acute lymphoblastic leukemia.
Authors: Leonardo Mirandola, Maurizio Chiriva-Internati, Everardo Cobos, Yuefei Yu, Jose A. Figueroa, Silvia Garavelli, Michela Colombo, Elisa Lazzari, Natalia Platonova, Kristopher Zepeda, Cynthia A. Jumper, Marjorie Jenkins, Raed Alalawi, Venu Konala, Amardeep Aulakh, Saba Radhi, Raffaella Chiaramonte
Journal: Journal of Clinical Oncology (2013)

7060 Background: Malignant cells from different cancers express different profiles of chemokine receptors (CKR). Their presence may influence site-specific spread of tumor cells, by enabling them to respond to chemokine gradient, and may increase cell sensibility to chemokine mediated proliferative and anti-apoptotic stimuli. Notch ability to positively regulate CKR has been reported: stimulation of Pax5-/- pre-B cells with the Notch ligand Delta-1 results in induction of transcripts for CCR4, CCR8 and CXCR 6; the Delta-1-dependent regulation of Langerhans cell development includes induction of CCR6 expression resulting in the activation of chemotactic response to MIP-1a; Notch controls CCR7 signaling a regulator of CNS infiltration in T-acute lymphoblastic leukemia (T-ALL). Methods: This work aims to explore the correlation between the activation of the Notch oncogenic pathway in T-ALL and multiple myeloma (MM) cells and the aberrant expression CKR. Human T-ALL cell lines were treated with the Notch activation inhibitor, DAPT, or with a potent inhibitor of the Notch target, C-MYC, and evaluated the expression and functions of CCR9, CCR5, and CXCR4. Results: Treatment of human T-ALL and MM cell lines with pharmacologic inhibitors of Notch receptor activation produced a significant reduction of CCR9, CCR5 and CXCR4 expression, at both mRNA and protein levels. Results were confirmed by chemotaxis and survival assays. We identified the product of C-MYC gene as a possible mediator of Notch effect in regulating CKR networks in T-ALL and MM. Conclusions: These results suggest that Notch receptors play a previously unknown role in cancer progression and metastasis, by maintaining the expression levels of CKR. In conclusion, the identification of the potential axis Notch/CKR could have a prognostic value and provide the rationale for a tailored approach, since both Notch and CKR are targeted by emerging drugs.
MYOCARDIAL STRAIN PATTERN AND HISTORY OF ATRIAL FIBRILLATION ARE ASSOCIATED WITH THE RISK OF VENTRICULAR ARRHYTHMIAS IN MITRAL VALVE PROLAPSE
Authors: Kristian Ujka, Yasufumi Nagata, Philippe B. Bertrand, Carl T. Andrews, Wei He, Michael Picard, Robert A. Levine, Judy Hung
Journal: Journal of the American College of Cardiology (2020)
Covid-19: cases grow in US as Trump pushes promise of a malaria drug
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

President Trump has told Americans that the covid-19 threat is serious, reversing his earlier position of telling Americans to relax because the coronavirus threat would soon pass. He called himself a “wartime president” and invoked an old defence production act to direct factories to produce protective equipment for healthcare workers and ventilators.

On 19 March, Johns Hopkins Center for Systems Engineering and Science reported that the US had 13 678 cases of covid-18 and 200 deaths. The states of California, New York, and Washington are most affected.1

New York City’s mayor, Bill de Blasio, asked for military aid to help deliver 15 000 ventilators and millions of surgical masks, gowns, coveralls, gloves, and face masks. On 19 March, the number of confirmed cases in the city almost doubled in a day to 3615. …
Generalization of the resource-rationality principle to neural control of goal-directed movements
Authors: Natalia Dounskaia, Yury P Shimansky
Journal: Behavioral and Brain Sciences (2020)

Abstract We review evidence that the resource-rationality principle generalizes to human movement control. Optimization of the use of limited neurocomputational resources is described by the inclusion of the “neurocomputational cost” of sensory information processing and decision making in the optimality criterion of movement control. A resulting tendency to decrease this cost can account for various phenomena observed during goal-directed movements.
Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?
Authors: Shona S. Fielding, Marielle Pijnenburg, Johan de Jongste, Katherine Pike, Graham Roberts, Helen Petsky, Anne B. Chang, Maria Fritsch, Thomas Frischer, Stanley J. Szefler, Peter Gergen, Francoise Vermeulen, Robin Vael, Steve S. Turner
Journal: European Respiratory Journal (2020)

Introduction Exhaled nitric oxide fraction ( F ENO ), a biomarker of eosinophilic airway inflammation, may be useful to guide asthma treatment. F ENO -guided treatment may be more effective in certain subgroups for improving asthma outcomes compared to standard treatment. Methods An individual patient data analysis was performed using data from seven randomised clinical trials (RCTs) which used F ENO to guide asthma treatment. The incidence of an asthma exacerbation and loss of control, and the time to first exacerbation and loss of control were described between five subgroups of RCT participants. Results Data were available in 1112 RCT participants. Among those not treated with leukotriene receptor antagonists (LTRA), but not among those who were treated with LTRA, F ENO -guided treatment was associated with reduced exacerbation risk (OR 0.68, 95% CI 0.49–0.94), longer time to first exacerbation (hazard ratio (HR) 0.76, 95% CI 0.57–0.99) and borderline reduced risk for loss of control (OR 0.70, 95% CI 0.49–1.00). Nonobese children, compared to obese children, were less likely to lose asthma control when treatment was guided by F ENO (OR 0.69, 95% CI 0.48–0.99) and time to loss of control was longer (HR 0.77, 95% CI 0.61–0.99). Conclusions Asthma treatment guided by F ENO may be more effective in achieving better asthma outcomes for patients who are not treated with LTRA and who are not obese, compared to standard practice.
Muscarinic M1 Receptors Modulate Working Memory Performance and Activity via KCNQ Potassium Channels in the Primate Prefrontal Cortex
Authors: Veronica C. Galvin, Sheng Tao Yang, Constantinos D. Paspalas, Yang Yang, Lu E. Jin, Dibyadeep Datta, Yury M. Morozov, Taber C. Lightbourne, Adam S. Lowet, Pasko Rakic, Amy F.T. Arnsten, Min Wang
Journal: Neuron (2020)